Abstract: A cosmetic composition including a water phase, the water phase comprising solubilized 4-hydroxyacetophenone with niacinamide, wherein the weight ratio of niacinamide to 4-hydroxyacetophenone in the water phase is greater than 3.0.

Abstract: The present invention relates to microcapsules comprising a core, wherein the core comprises cinmethylin, and a polyurea shell, wherein the shell comprises a polyaddition product of diphenylmethane diisocyanate or an oligomer thereof and at least one amine having at least two primary amino groups; to a composition comprising such microcapsules; to a method for preparing such microcapsules or such a composition; to a composition obtainable by said preparation method; and to the use of such microcapsules or compositions for controlling undesired vegetation.

Abstract: The invention provides high viscosity, low polyol compositions. By using surfactant system wherein 50% or more of the surfactant system comprises a surfactant of defined Vh/Icao value, it is possible to provide such composition having good foam appearance. If surfactants of such value are not used, the high polyol, low viscosity composition have “bad” foam attributes (not “self-foaming), when measured for example after pumping through mechanical pump (composition has 0 to 0.5% propellant gel or gas).

Abstract: Dynamic make-up product having in its formulation magneto-chromatic microspheres, which modify their orientation and therefore the color of the make-up product under the action of a magnetic field, wherein said dynamic make-up product, once exhausted, is configured to be recharged by means of a refill containing interchangeable capsules inside which the dynamic make-up product is contained. The refill is inserted in a casing having all the magnetic side surfaces which cooperate with a magnetic field source generating a magnetic force.

Abstract: According to the present disclosure, a method of preparing polymeric microparticles comprising further crosslinking with an organic crosslinking agent after crosslinking with metal ions, polymeric microparticles, medical compositions, cosmetic compositions, medical articles and cosmetic articles comprising the same can be provided.

Abstract: The present disclosure provides porous composite powder which includes biodegradable polymer particles with a porous structure having positive charges dispersed uniformly thereon and further includes inorganic particles. The porous composite powder adsorbs and removes fine particulate matter remaining in the skin and skin pores effectively through ionic bonding, while maintaining a spherical shape. The present disclosure also provides a method for preparing porous composite powder for adsorption of fine dust including particles forming a composite homogeneously, while maintaining a spherical shape, through a single process.

Abstract: Compositions and methods are provided for treating first, second degree burns to rapidly minimize hyperkalemia, hyponatremia, blistering, and pain management by externally applying gel mixture on unopened injured burn areas from onset of burn shock. The substrate is a gel mixture matrix containing concentrated sodium ion that creates a concentration gradient, allowing in situ diffusion of sodium ion (in vitro) into blister, edema, and extracellular fluids (in vivo) to reduce hyponatremia and (in situ), delivering the pH control constituents in vivo to prevent initial acidosis, followed by minimizing subsequent alkalosis and normalizing SID while simultaneously in situ expelling potassium ions in vitro from the same fluids transdermally while restoring normal homeostasis.

Abstract: The present disclosure relates to an aqueous micellar liquid composition that include an amphoteric surfactant, an alkyl glucoside and a specific preservative system. In particular, the compositions include: a) an amphoteric surfactant; b) an alkyl glucoside and c) sodium benzoate. The compositions are low foaming upon rubbing and stable.

Abstract: In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example pruritus, a disorder related to elevated serum cholesterol concentration, or reducing elevated low-density lipoprotein cholesterol (LDL) concentration in a patient.

Abstract: Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum.

Abstract: The disclosure relates to the field of reducing malodor, which is due to bacterial conversion of molecules that are present in sweat. Indeed, the disclosure describes acids, which steer the microbiome by inhibiting the growth of specific malodor-producing bacteria and/or promoting the growth of bacteria known to be beneficial in relation to malodor. The acids of the disclosure can thus be used in deodorants, washing powders, clothing finishing agents or any method to reduce malodor. The disclosure thus relates to a topical composition or textile finisher for use as a prebiotic.

Abstract: Disclosed are an ethanol hardener and the use thereof. The ethanol hardener contains ethanol, a water-soluble iodine preparation and water, wherein the volume percent of the ethanol is 76-98%, and the mass-volume ratio of the iodine element in the water-soluble iodine preparation to the iodine containing composition is 23-139 g/L. The iodine containing composition can be autoradiographed when injected into blood vessels, and has a better embolization effect and stability.

Abstract: The present invention relates to improved formulations of propandiol mononitrate and derivatives thereof as well as to the production of such formulations.

Abstract: A discrete dispensed product comprising a first portion; and a second portion at least partially surrounding the first portion provides a premium and distinct appearance to consumers.

Abstract: Methods of making polytetrafluoroethylene (PTFE)/polymer composites are disclosed herein. The products can be used in the field of bio- and medical applications, such as for use in artificial blood vessels, vascular grafts, cardiovascular and soft tissue patches, facial implants, surgical sutures, and endovascular prosthesis, and for any products known in the aerospace, electronics, fabrics, filtration, industrial and sealant arts.

Abstract: The present invention relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogel formulations comprising at least one antibiotic for relieving and/or treating low back pain.

Abstract: The present invention is in the field of antiperspirant compositions, in particular, compositions comprising antiperspirant actives. Disclosed is an anhydrous antiperspirant composition comprising an inorganic polyionic cluster having structure of (I) or (II); where M is Ca or Mg; and wherein the composition is substantially free of abrasives, which means less than 3.0% by weight of the composition; wherein anhydrous means the water content of the composition is less than 3.0%.

Abstract: The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

Abstract: This invention provides for a gel texturizer base for cosmetic products. The bases are excipients that provide a gel-like texture to cosmetic products. The gel texturizer bases of this invention are from non-petroleum based products and comprise over 85% juice derived solvent with the balance being a combination of a texture enhancer and a gum texture modifier.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.